Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non Operating Income for 11 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 94.15% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 93.95% increase, with the full-year FY2025 number at -$2.0 million, up 93.95% from a year prior.
  • Non Operating Income was -$2.0 million for Q4 2025 at Cartesian Therapeutics, down from -$5000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $508000.0 in Q1 2024 to a low of -$34.3 million in Q4 2024.
  • A 5-year average of -$2.3 million and a median of $154000.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 25200.0% in 2023, then crashed 55206.45% in 2024.
  • Cartesian Therapeutics' Non Operating Income stood at $9000.0 in 2021, then surged by 1844.44% to $175000.0 in 2022, then plummeted by 135.43% to -$62000.0 in 2023, then plummeted by 55206.45% to -$34.3 million in 2024, then skyrocketed by 94.15% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Non Operating Income are -$2.0 million (Q4 2025), -$5000.0 (Q2 2025), and -$34.3 million (Q4 2024).